-
EP4257604
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4257604
| EP4257604 - ANTI-TSLP ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 08.09.2023 Database last updated on 27.07.2024 | |
| Former | The international publication has been made Status updated on 14.06.2022 | Most recent event Tooltip | 19.07.2024 | Change - classification | published on 21.08.2024 [2024/34] | 19.07.2024 | Change - classification | published on 21.08.2024 [2024/34] | Applicant(s) | For all designated states Jiangsu Hengrui Pharmaceuticals Co., Ltd. No. 7 Kunlunshan Road Economic and Technological Development Zone Lianyungang, Jiangsu 222047 / CN | For all designated states Shanghai Hengrui Pharmaceutical Co., Ltd No.279 Wenjing Road Economic and Technological Development Zone Minhang District Shanghai 200245 / CN | [2023/41] | Inventor(s) | 01 /
WANG, Zhiwan Shanghai 200245 / CN | 02 /
WU, Tingting Shanghai 200245 / CN | 03 /
LIU, Xun Shanghai 200245 / CN | [2023/41] | Representative(s) | Broom, Ashley John GlaxoSmithKline 980 Great West Road Brentford, Middlesex TW8 9GS / GB | [N/P] |
| Former [2023/41] | dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB Deichmannhaus am Dom Bahnhofsvorplatz 1 50667 Köln / DE | Application number, filing date | 21899892.0 | 22.11.2021 | [2023/41] | WO2021CN132037 | Priority number, date | CN202011405207 | 03.12.2020 Original published format: CN202011405207 | [2023/41] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022116858 | Date: | 09.06.2022 | Language: | ZH | [2022/23] | Type: | A1 Application with search report | No.: | EP4257604 | Date: | 11.10.2023 | Language: | EN | [2023/41] | Search report(s) | International search report - published on: | CN | 09.06.2022 | Classification | IPC: | C07K16/24, C12N15/13, A61K39/395 | [2023/41] | CPC: |
C07K16/244 (EP,KR,US);
A61K39/39591 (EP,KR,US);
A61K47/12 (US);
A61K47/183 (EP);
A61K47/186 (US);
A61K47/22 (KR,US);
A61K47/26 (EP,KR,US);
A61K9/19 (EP,KR);
A61P35/00 (KR);
A61P37/00 (KR);
A61P37/08 (KR);
A61K2039/505 (KR);
C07K2317/24 (EP,US);
C07K2317/33 (EP);
C07K2317/56 (EP);
C07K2317/565 (EP);
C07K2317/567 (US);
C07K2317/73 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/41] | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT ANTI-TSLP-ANTIKÖRPER UND VERWENDUNG DAVON | [2023/41] | English: | ANTI-TSLP ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF | [2023/41] | French: | COMPOSITION PHARMACEUTIQUE D'ANTICORPS ANTI-TSLP ET SON UTILISATION | [2023/41] | Entry into regional phase | 03.07.2023 | Translation filed | 03.07.2023 | National basic fee paid | 03.07.2023 | Search fee paid | 03.07.2023 | Designation fee(s) paid | 03.07.2023 | Examination fee paid | Examination procedure | 03.07.2023 | Amendment by applicant (claims and/or description) | 03.07.2023 | Examination requested [2023/41] | Fees paid | Renewal fee | 03.07.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | |||